MBRX - Moleculin Biotech, Inc.
2.53
-0.030 -1.186%
Share volume: 58,880
Last Updated: 04-21-2026
Pharmaceutical Products/Pharmaceutical Preparations:
3.15%
PREVIOUS CLOSE
CHG
CHG%
$2.56
-0.03
-0.01%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 06-30-2025 | 09-30-2025 | 12-31-2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
| Report Date | 05-10-2024 | 08-13-2024 | 11-08-2024 | 03-21-2025 | 05-13-2025 | 08-12-2025 | 11-13-2025 | 03-18-2026 | |
| Assets | |||||||||
| Total Assets | 30.845 M | 25.575 M | 23.394 M | 16.925 M | 21.013 M | 21.593 M | 20.353 M | 22.126 M | |
| Current Assets | 18.957 M | 13.731 M | 11.606 M | 5.194 M | 9.340 M | 9.076 M | 7.885 M | 9.686 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Investments | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Receivables | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current Cash | 16.824 M | 10.845 M | 9.405 M | 4.278 M | 7.716 M | 7.557 M | 6.703 M | 8.878 M | |
| Total Non-current Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Property Plant Equipment | 240.000 K | 221.000 K | 190.000 K | 159.000 K | 127.000 K | 99.000 K | 77.000 K | 78.000 K | |
| Other Assets | 11.648 M | 11.623 M | 11.598 M | 11.572 M | 11.546 M | 12.418 M | 12.391 M | 12.362 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 30.845 M | 25.575 M | 23.394 M | 16.925 M | 21.013 M | 21.593 M | 20.353 M | 22.126 M | |
| Total liabilities | 9.258 M | 7.870 M | 15.915 M | 10.946 M | 20.971 M | 28.758 M | 47.273 M | 7.120 M | |
| Total current liabilities | 5.408 M | 5.746 M | 5.593 M | 5.359 M | 6.896 M | 7.913 M | 5.682 M | 6.854 M | |
| Accounts Payable | 2.104 M | 2.833 M | 2.550 M | 2.030 M | 2.706 M | 3.721 M | 2.116 M | 3.508 M | |
| Other liabilities | 3.850 M | 2.124 M | 10.322 M | 5.587 M | 14.075 M | 20.845 M | 41.591 M | 266.000 K | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 3.850 M | 2.124 M | 10.322 M | 5.587 M | 14.075 M | 20.845 M | 41.591 M | 266.000 K | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 21.587 M | 17.705 M | 7.479 M | 5.979 M | 42.000 K | -7.165 M | -26.920 M | 15.006 M | |
| Common stock | 158.179 M | 158.608 M | 158.960 M | 159.387 M | 159.883 M | 160.316 M | 194.680 M | 221.000 M | |
| Retained earnings | -136.574 M | -140.893 M | -151.485 M | -153.367 M | -159.803 M | -167.443 M | -221.556 M | -206.004 M |